Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Assets (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Other Non-Current Assets for 5 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets changed 0.19% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2025, changed 0.19%, and an annual FY2024 reading of $170000.0, down 55.26% over the prior year.
  • Other Non-Current Assets was $1.0 million for Q3 2025 at Autolus Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.2 million in Q4 2022 and bottomed at $116000.0 in Q1 2025.
  • Average Other Non-Current Assets over 4 years is $828818.2, with a median of $977000.0 recorded in 2024.
  • The sharpest move saw Other Non-Current Assets crashed 92.08% in 2023, then soared 659.56% in 2024.
  • Year by year, Other Non-Current Assets stood at $2.2 million in 2022, then tumbled by 82.54% to $380000.0 in 2023, then crashed by 55.26% to $170000.0 in 2024, then skyrocketed by 506.47% to $1.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for AUTL at $1.0 million in Q3 2025, $1.1 million in Q2 2025, and $116000.0 in Q1 2025.